Copyright Seeking Alpha
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth Oct. 30, 2025 12:07 AM ETGlaukos Corporation (GKOS) StockAI-Generated Earnings Calls Insights Comments Earnings Call Insights: Glaukos Corporation (GKOS) Q3 2025 Management View CEO Thomas Burns began by highlighting "record third quarter consolidated net sales of $133.5 million, up 38% on a reported basis or 37% on a constant currency basis versus the year ago quarter." He announced an Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Quick Insights Analysts and management both highlighted considerable risks around Epioxa’s $78,500 price point, with concerns over payer education, patient access, and potential headwinds in reimbursement. Strong iDose TR adoption and momentum, FDA approval and upcoming launch of Epioxa, and continued gross margin gains are key factors in the upgraded 2025 guidance and the preliminary 2026 range of $600 million to $620 million. Management warns of a year-over-year Corneal Health decline during Epioxa’s roll-out due to Photrexa’s staged discontinuation and payer coverage uncertainty for the new drug. Recommended For You More Trending News
